Compare CSPI & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSPI | RANI |
|---|---|---|
| Founded | 1968 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.8M | 134.6M |
| IPO Year | 1987 | 2021 |
| Metric | CSPI | RANI |
|---|---|---|
| Price | $13.01 | $1.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 23.2K | ★ 2.6M |
| Earning Date | 12-16-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $58,730,000.00 | $1,200,000.00 |
| Revenue This Year | N/A | $414.59 |
| Revenue Next Year | N/A | $30.15 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.36 | N/A |
| 52 Week Low | $9.65 | $0.39 |
| 52 Week High | $21.95 | $3.87 |
| Indicator | CSPI | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 51.63 | 42.10 |
| Support Level | $12.74 | $1.40 |
| Resistance Level | $13.78 | $1.53 |
| Average True Range (ATR) | 0.96 | 0.11 |
| MACD | -0.10 | -0.00 |
| Stochastic Oscillator | 30.79 | 15.00 |
CSP Inc develops and markets IT integration solutions, security products, managed IT services, cloud services, purpose-built network adapters, and high-performance cluster computer systems. The firm operates in two segments, namely Technology Solutions, where the company focuses on value-added reseller integrated solutions, including third-party hardware, software, and technical computer-related consulting, and High-Performance Products segments, where the company designs, manufactures, and delivers products and services to customers that require specialized cybersecurity services, networking, and signal processing. It generates a majority of its revenue from the Technology Solutions segment. Geographically, the company generates the majority of its revenue from the Americas.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.